Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)

Gilead Sciences (GILD) reported Amortizatization of Intangibles of $596.0 million for Q1 2026, down 0.5% on a YoY basis from $599.0 million in Q1 2025, and little changed quarter-over-quarter from $597.0 million in Q4 2025.

Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Amortizatization of Intangibles for 18 years, with the latest figure at $596.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Amortizatization of Intangibles fell 0.5% year-over-year to $596.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (changed 0.08% YoY), and the FY2025 full-year result was $2.4 billion, changed 0.17% from the prior year.
  • Amortizatization of Intangibles for Q1 2026 stood at $596.0 million, roughly flat from $597.0 million in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $599.0 million in Q1 2025, with the low at $445.0 million in Q1 2022.
  • Historically, Amortizatization of Intangibles has averaged $558.3 million across 5 years, with a median of $596.0 million in 2024.
  • Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 34.38% — and 2026, when it dropped 0.5%.
  • Gilead Sciences' Amortizatization of Intangibles stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then increased by 0.17% to $598.0 million in 2024, then dropped by 0.17% to $597.0 million in 2025, then slipped by 0.17% to $596.0 million in 2026.
  • The last three Amortizatization of Intangibles figures came in at $596.0 million (Q1 2026), $597.0 million (Q4 2025), and $596.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 1.70 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 931.00 Mn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 596.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 596.00 Mn
Mar 31, 2026 596.00 Mn
Dec 31, 2025 597.00 Mn
Dec 31, 2025 597.00 Mn
Sep 30, 2025 596.00 Mn
Sep 30, 2025 596.00 Mn
Jun 30, 2025 598.00 Mn
Jun 30, 2025 598.00 Mn
Mar 31, 2025 599.00 Mn
Mar 31, 2025 599.00 Mn
Dec 31, 2024 598.00 Mn
Dec 31, 2024 598.00 Mn
Sep 30, 2024 596.00 Mn
Sep 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn
Dec 31, 2023 597.00 Mn
Dec 31, 2023 597.00 Mn